Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

122.61 +0.81 (+0.67%)
Official Closing Price Updated: 7:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
50 51 Next >
Why Novartis Shares Are Trading Higher Premarket Today
Novartis AG (NYSE: NVS) shares are trading higher in the premarket session after its breast cancer drug showed clinical benefit in early-stage breast cancer. 
Via Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
New research project aims to set standardized approach to lipoprotein(a) management
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
How Is The Market Feeling About Novartis?
 
Via Benzinga
2 Biotech Stocks That Could Make You Richer
One is a well-established, large-cap drugmaker, while the other is still making a name for itself in the industry. 
Via The Motley Fool
FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations
 
Via Benzinga
This High-Yielding Blue Chip Stock Is a Strong Buy
This big pharma company pays a market-topping dividend to shareholders. 
Via The Motley Fool
Top CRISPR Stocks
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. 
Via Benzinga
Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years
 
Via Benzinga
Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories
Benzinga 
Via Benzinga
Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues
Last week the FDA said Novartis AG's (NYSE: NVS) Pluvicto is short in supply due to manufacturing and delivery issues.  Pluvicto is a radiopharmaceutical medication used for prostate-specific membrane... 
Via Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival... 
Via FinancialNewsMedia
3 High Dividend Stocks With Attractive Total Return Potential
In the current economic environment, it is crucial for investors to prioritize quality, reliable dividend stocks and high total returns. 
Via InvestorPlace
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
By David Willey, Benzinga 
Via TheNewswire.com
Topics Economy
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
With the growing use of AI in healthcare, it has led to a number of stocks that are focused on this industry. 
Via InvestorPlace
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
Texas-based biotech company, Coya Therapeutics (NASDAQ: COYA), is positioning itself as a leader in a promising area of the medical field. 
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
 
Via Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
Lupus Therapeutics Market Is on the Verge of Crossing at High CAGR of 9% in 2022-2029
The global lupus therapeutics market is expected to reach a CAGR of 9% during the forecast period (2022-2029). 
Via SBWire
Bladder Prolapse (Cystocele) Market to Touch at High CAGR of 8.3% by 2022-2029
Bladder Prolapse (cystocele) Market is expected to grow at a CAGR of 8.3 % during the forecast period (2022-2029). 
Via SBWire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer... 
Via SBWire
Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029
Occupational medicines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.4 % during the forecast period (2022-2029). 
Via SBWire
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
 
Via Benzinga
Water for Injection Market Trends Outlook Demand 2023 -2030
Global Water for Injection Market to Witness Huge Growth by Key Players: Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International... 
Via SBWire
Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
Enterprise software maker Snowflake notched a three-month gain of 28.85%, far outpacing the S&P 500’s return of 9.32%. Analysts expect the price to rise 19%. 
Via MarketBeat
Topics Stocks
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030) 
Via SBWire
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.